|
Suppliers for CAS
649735-46-6
|
Properties | | CAS |
649735-46-6 | | Formula |
C19H19FN4O3 |
|
|
6 Registered suppliers
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C19H19FN4O3
Molecular Weight: 370.382
Aea.ltd
P.R.China
Molecular Formula: C19H19FN4O3
Molecular Weight: 370.382
Molecular Formula: C19H19FN4O3
Molecular Weight: 370.382
Hangzhou Zhongqi Chem Co., Ltd
P.R.China
Molecular Formula: C19H19FN4O3
Molecular Weight: 370.382
BOC Sciences
USA
Description : Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :370.37756
Molecular Formula : C19H19FN4O3 Canonical SMILES : CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C
InChI :
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChIKey :
WCWUXEGQKLTGDX-LLVKDONJSA-N
Synonyms :
BMS540215; BMS-540215; BMS 540215.
More details are to be found here
Chemos GmbH & Co. KG
Germany
Description : Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :370.37756
Molecular Formula : C19H19FN4O3 Canonical SMILES : CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C
InChI :
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChIKey :
WCWUXEGQKLTGDX-LLVKDONJSA-N
Synonyms :
BMS540215; BMS-540215; BMS 540215.
More details are to be found here
Santa Cruz Biotechnology, Inc.
USA
Description : Brivanib is the hydrolyzed form of Brivanib alaninate, which is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for active clinical trials or closed clinical trials using this agent. - Molecular Weight :370.37756
Molecular Formula : C19H19FN4O3 Canonical SMILES : CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C
InChI :
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChIKey :
WCWUXEGQKLTGDX-LLVKDONJSA-N
Synonyms :
BMS540215; BMS-540215; BMS 540215.
More details are to be found here
Detailed information on the suppliers of
Brivanib |
details
details